Christopher P. Cannon

TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING CORONARY ARTERY BY-PASS SURGERY: RESULTS FROM THE PLATO TRIAL

C. Held, C. Cannon, K. Mahaffey, 2010 .

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

C. Cannon, D. Kereiakes, P. Minini, 2016, Coronary artery disease.

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Jennifer G. Robinson, J. D. Jordan, G. Molenberghs, 2016, Journal of the American Heart Association.

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies

Jennifer G. Robinson, C. Cannon, N. Sattar, 2018, Diabetes Therapy.

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.

C. Cannon, D. Rader, M. Banach, 2018, Kidney international.